Sill H et al., 2011-02: Narrative review of therapy-related myeloid neoplasms covering the drug classes that cause them (alkylators, topoisomerase II inhibitors, antimetabolites, radiation, G-CSF) and the mutational pathobiology.
t-MNs are observed after ionizing radiation as well as conventional chemotherapy including alkylating agents, topoisomerase-II-inhibitors and antimetabolites.
Abstract
Sill H et al., 2011-02: Narrative review of therapy-related myeloid neoplasms covering the drug classes that cause them (alkylators, topoisomerase II inhibitors, antimetabolites, radiation, G-CSF) and the mutational pathobiology. Comparator: none (review). Funder/COI not in the abstract; PMC deposit is abstract-only to this client. Topoisomerase-II-inhibitor t-MNs are characterised by balanced translocations and alkylator t-MNs by complex karyotypes/p53 mutation. The commonly repeated latency figures (roughly 5-7 years for alkylators, 1-3 years for topo II inhibitors) were NOT located verbatim in any full text opened this run, so they are not quoted here. Study type: review.
